"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • For Professionals
  • Drug Updates
  • Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival for Patients with Advanced Hodgkin's Lymphoma

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival for Patients with Advanced Hodgkin's Lymphoma

26 May 2022 5:30 AM | Katy Monaco (Administrator)

Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma.  Read More.

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software